Latest Commercial Rollouts News

Micro-X has raised $6.18 million through a placement that sees strategic partner Billion Prima increase its stake to 8.6%, funding key commercial and manufacturing scale-up initiatives in medical imaging.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Ovanti’s US payments brand Flote has partnered with cloud-native platform Gr4vy to launch scalable, responsible buy now pay later solutions in the US market starting 2026.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

Skin Elements Limited has completed a $2.5 million placement to fund the commercial rollout of its ECO Nurture bio-stimulant, targeting sustainable kiwifruit orchard protection in New Zealand.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Ovanti Limited’s US subsidiary has secured a key partnership with Mastercard’s Finicity to enhance its upcoming Flote BNPL platform, aiming to revolutionize consumer finance with real-time data insights.

Identitii Limited launches a $2.9 million rights issue, underwritten up to $2.3 million by its largest shareholder, to accelerate the commercial rollout of its BNDRY platform.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Control Bionics has secured $3.25 million through a discounted share placement, aiming to boost its assistive and neurotechnology product growth globally.